tetano
Editor, Senior Moderator
Vaccine
. 2020 Oct 30;S0264-410X(20)31330-X.
doi: 10.1016/j.vaccine.2020.10.036. Online ahead of print.
Repeated exposure to an MF-59 adjuvanted quadrivalent subunit influenza vaccine (aQIV) in children: Results of two revaccination studies
Timo Vesikari[SUP] 1 [/SUP], K Ramsey[SUP] 2 [/SUP], P Pitisuttithum[SUP] 3 [/SUP], R Capeding[SUP] 4 [/SUP], Esther Heijnen[SUP] 5 [/SUP], Daphne Sawlwin[SUP] 6 [/SUP], Janine Obery?[SUP] 7 [/SUP], Bin Zhang[SUP] 8 [/SUP], Igor Smolenov[SUP] 8 [/SUP]
Affiliations
Abstract
Background: Pediatric adjuvanted seasonal influenza vaccines induce higher immune responses and have the potential to confer better protection against influenza among young vaccine-na?ve children. Limited data describe benefits and risks of repeated administration of adjuvanted influenza vaccines in children. Two revaccination studies assess the safety and immunogenicity of repeated exposure to an MF59-adjuvanted quadrivalent influenza vaccine (aQIV; Fluad?) compared to routine non-adjuvanted quadrivalent influenza vaccine (QIV).
Methods: Children previously enrolled in the parent study, who received vaccination with aQIV or nonadjuvanted influenza vaccine (TIV or QIV), were recruited in Season 1 (n = 607) or Season 2 (n = 1601) of the extension trials. Season 1 participants remained in their original randomization groups (aQIV-aQIV or TIV-QIV); Season 2 subjects were re-randomized to either vaccine, resulting in four groups (aQIV-aQIV, aQIV-QIV, QIV-aQIV, or QIV-QIV). All subjects received a single-dose vaccination. Blood samples were taken for immunogenicity assessment prior to vaccination and 21 and 180 days after vaccination. Reactogenicity (Days 1-7) and safety were assessed in all subjects.
Results: Hemagglutination inhibition (HI) geometric mean titer (GMT) ratios demonstrated superiority of aQIV revaccination over QIV revaccination for all strains in Season 1 and for A/H1N1, B/Yamagata, and B/Victoria in Season 2. Higher HI titers against heterologous influenza strains were observed after aQIV vaccination during both seasons. Mild to moderate severity and short duration reactogenicity was more common in the aQIV than QIV groups, but the overall safety profiles were similar to the parent study.
Conclusion: The safety and immunogenicity results from this study demonstrate benefit of aQIV for both priming and revaccination of children aged 12 months to 7 years.
Keywords: Immunogenicity; Influenza vaccine; MF59 adjuvant; Revaccination; Safety.
. 2020 Oct 30;S0264-410X(20)31330-X.
doi: 10.1016/j.vaccine.2020.10.036. Online ahead of print.
Repeated exposure to an MF-59 adjuvanted quadrivalent subunit influenza vaccine (aQIV) in children: Results of two revaccination studies
Timo Vesikari[SUP] 1 [/SUP], K Ramsey[SUP] 2 [/SUP], P Pitisuttithum[SUP] 3 [/SUP], R Capeding[SUP] 4 [/SUP], Esther Heijnen[SUP] 5 [/SUP], Daphne Sawlwin[SUP] 6 [/SUP], Janine Obery?[SUP] 7 [/SUP], Bin Zhang[SUP] 8 [/SUP], Igor Smolenov[SUP] 8 [/SUP]
Affiliations
- PMID: 33139136
- DOI: 10.1016/j.vaccine.2020.10.036
Abstract
Background: Pediatric adjuvanted seasonal influenza vaccines induce higher immune responses and have the potential to confer better protection against influenza among young vaccine-na?ve children. Limited data describe benefits and risks of repeated administration of adjuvanted influenza vaccines in children. Two revaccination studies assess the safety and immunogenicity of repeated exposure to an MF59-adjuvanted quadrivalent influenza vaccine (aQIV; Fluad?) compared to routine non-adjuvanted quadrivalent influenza vaccine (QIV).
Methods: Children previously enrolled in the parent study, who received vaccination with aQIV or nonadjuvanted influenza vaccine (TIV or QIV), were recruited in Season 1 (n = 607) or Season 2 (n = 1601) of the extension trials. Season 1 participants remained in their original randomization groups (aQIV-aQIV or TIV-QIV); Season 2 subjects were re-randomized to either vaccine, resulting in four groups (aQIV-aQIV, aQIV-QIV, QIV-aQIV, or QIV-QIV). All subjects received a single-dose vaccination. Blood samples were taken for immunogenicity assessment prior to vaccination and 21 and 180 days after vaccination. Reactogenicity (Days 1-7) and safety were assessed in all subjects.
Results: Hemagglutination inhibition (HI) geometric mean titer (GMT) ratios demonstrated superiority of aQIV revaccination over QIV revaccination for all strains in Season 1 and for A/H1N1, B/Yamagata, and B/Victoria in Season 2. Higher HI titers against heterologous influenza strains were observed after aQIV vaccination during both seasons. Mild to moderate severity and short duration reactogenicity was more common in the aQIV than QIV groups, but the overall safety profiles were similar to the parent study.
Conclusion: The safety and immunogenicity results from this study demonstrate benefit of aQIV for both priming and revaccination of children aged 12 months to 7 years.
Keywords: Immunogenicity; Influenza vaccine; MF59 adjuvant; Revaccination; Safety.